Announced Mon, 17 Aug · 16:52 IST
Indrayani Biotech Q4 FY26: auditor gives qualified opinion on results
Qualified OpinionRevenue DeclinePat Growth 25pctNegative Operating CashflowResults View source PDFExplain this filing
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+2.2%1-day move
₹7.39
prior close
₹7.44
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.8-1.6-1.3+0.5+2.2+5.7+6.1+6.8+4.7+8.0+14.2+25.8——
Up moveDown movePending
AI summary
Indrayani Biotech posted consolidated FY26 revenue of Rs 13,783 lakhs (up 6% from Rs 13,023 lakhs). Net profit swung from a loss of Rs 611 lakhs to a profit of Rs 216 lakhs. Standalone revenue fell 42% to Rs 2,190 lakhs. Auditor issued a qualified opinion due to unconfirmed loans, receivables and subsidiary accounts.
Likely market impact
Qualified opinion and standalone revenue drop raise concerns, though consolidated turnaround to profit is a positive.